(News Bulletin 247) – Roche on Friday reported new favorable phase III data for crovalimab, its experimental treatment for paroxysmal nocturnal hemoglobinuria, a rare blood disease.
According to the company, the results of the ‘Commodore 2’ study showed that crovalimab successfully controlled the disease in patients who had not previously been treated with complement inhibitors.
Results from the ‘Commodore 1’ trial – conducted in patients switching from currently approved C5 protein inhibitors to crovalimab – meanwhile established that 79.3% of them had managed to control their haemolysis, compared to 79 % in the eculizumab group, a drug from Alexion.
Paroxysmal nocturnal hemoglobinuria – a condition in which red blood cells are destroyed by the immune system causing anemia, fatigue, blood clots and kidney disease – can be life-threatening.
These data were presented at the European Hematology Association Congress, which opened today in Frankfurt.
Copyright (c) 2023 News Bulletin 247. All rights reserved.
I have over 8 years of experience working in the news industry. I have worked as a reporter, editor, and now managing editor at 247 News Agency. I am responsible for the day-to-day operations of the news website and overseeing all of the content that is published. I also write a column for the website, covering mostly market news.
